Skip to main content
SpringerLink
Log in

Bedeutung der Elimination von Campylobacter pylori in der Ulkustherapie

  • Conference paper
Book cover Aktuelle Gastroenterologie — Campylobacter pylori

  • 9 Accesses

Zusammenfassung

Bevor zur Elimination von Campylobacter pylori als therapeutischem Ziel in der Behandlung von Ulcera duodeni Stellung genommen werden kann, muß die Frage der Indikation hierfür geklärt werden und damit auch die Frage nach der Pathogenität von Campylobacter pylori (C. pylori) hinreichend beantwortet sein.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bayerdörffer E, Kasper G, Pirlet Th, Sommer A, Ottenjann R (1988) Ofloxacin in der Therapie „resistenter“Ulcera duodeni. Z Gastroenterol, im 26: 155

    Google Scholar 

  2. Bayerdörffer E, Kasper G, Pirlet Th, Sommer A, Ottenjann R (1987) Ofloxacin in der Therapie Campylobacter pylori positiver Ulcera duodeni. Dtsch Med Wschr 112:1407

    Article  PubMed  Google Scholar 

  3. Bayerdörffer E, Kasper G, Sommer A, Ottenjann R (1987) Is Campylobacter pylori a pathogenic factor in duodenal ulcer? Abstract No. 13 IVth International Workshop on Campylobacter Infections, Göteborg, Sweden, June 16–18

    Google Scholar 

  4. Bayerdörffer E, Simon Th, Bästlein Ch, Kasper G, Ottenjann R (1987) Bismuth/ ofloxacin combination for duodenal ulcer. Lancet ii: 1467

    Article  Google Scholar 

  5. Bianchi Porro G, Barbara L, Cheli R, Dalmonte PR, Mazzacca G (1984) Comparison of tripotassium dicitrato bismuthate (TDB) tablets and ranitidine in healing and relapse of duodenal ulcers. Gut 25: A565

    Google Scholar 

  6. Bianchi Porro G, Lazzaroni M, Petrillo M, Nicola C (1984) Relapse rates in duodenal ulcer patients formerly treated with bismuth subcitrate or maintained with Cimetidine. Lancet ii: 698

    Article  Google Scholar 

  7. Bianchi Porro G, Parente F, Lazzaroni M, Pace F (1986) Colloidal bismuth subcitrate and two different dosages of Cimetidine in the treatment of resistant duodenal ulcer. Scand J Gastroenterol 21 [suppl. 122]: 39

    Article  Google Scholar 

  8. Blaser MJ (1987) Gastric Campylobacter-like organisms, gastritis, and peptic ulcer disease. Gastroenterol 93: 371

    CAS  Google Scholar 

  9. Bode G, Malfertheiner P, Ditschuneit H (1987) Invasion of Campylobacter-like organisms in the duodenal mucosa in patients with active duodenal ulcer. Klin Wschr 65: 144

    Article  PubMed  CAS  Google Scholar 

  10. Burette A, Glupczinski Y, Dereuck M, Labbe M, Deltenre M (1987) Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial with amoxicillin. Abstract No. 28, IVth International Workshop on Campylobacter Infections, Göteborg, Sweden, June 16–18

    Google Scholar 

  11. Caekenberghe DL van, Breyssens J (1987) In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori). Antimicrob Agents Chemother 31: 1429

    PubMed  Google Scholar 

  12. Carrick J, Daskalopoulos G, Hazell S, Ralston M, Lee A (1987) The role of Campylobacter pyloridis and gastric metaplasia in duodenal ulceration. Campylobacter pylori -A multi-disciplinary workshop, Keystone, Colorado, July 28–31

    Google Scholar 

  13. Coghlan JG, Gilligan D, Humphries H, McKenna D, Dooley C, Sweeney E, Keane C, O’Morain C (1987) Campylobacter pylori and recurrence of duodenal ulcers — A 12-month follow-up study. Lancet ii: 1109

    Article  Google Scholar 

  14. Coughlin GP, Kupa A, Alp MH (1977) The effect of tri-potassium dicitrato bismuthate (De-Nol) on the healing of chronic dudenal ulcers. Med J Aust 1: 294

    PubMed  CAS  Google Scholar 

  15. Crabtree JE, Rathbone BJ, Heatley RV, Wyatt JI, Losowsky MS (1987) In vitro glycoprotein synthesis and secretion in Campylobacter pyloridis associated chronic gastritis. Abstract No. 38, IVth International Workshop on Campylobacter Infections, Göteborg, Sweden, June 16–18

    Google Scholar 

  16. Czinn S, Carr H, Aronoff S (1986) Susceptibility of Campylobacter pyloridis to three macrolide antibiotics (erythromycin, roxithromycin [RU 28965], and CP 62,933] and rifampicin. Antimicrobial Agents and Chemotherapy 30: 328

    PubMed  CAS  Google Scholar 

  17. Eberhardt R, Kasper G, Dettmer A, Höchter W, Hagena D (1987) Effect of oral bismuthsubsalicylate on Campylobacter pyloridis and duodenal ulcer. Campylobacter pylori — A multi-discipinary workshop, Keystone, Colorado, July 28–31

    Google Scholar 

  18. Flavell Matts SG, Swan CHJ, Kellcher J (1965) Double-blind trial of bismuth alumi-nate and magnesium trisilicate in peptic ulceration with simultaneous gastric analysis. Br Med J 250: 753

    Article  Google Scholar 

  19. Gavrilenko YV, Parshkov EM, Pichugin YI, Skornetsky BD, Slepynin VI, Chibis OA (1976) Treatment of gastric and duodenal ulcer with metronidazole. Ter Arkh 48: 74

    PubMed  CAS  Google Scholar 

  20. Gilligan D, Coghlan G, Humphries H, McKenna D, Dooley C, Sweeney E, Keane C, O’Morain C (1987) Campylobacter pylori and recurrence of duodenal ulcers — An eighteen month follow up study. Abstract No. 235, IVth International Workshop on Campylobacter Infections, Göteborg, Sweden, June 16–18

    Google Scholar 

  21. Gilman R, Leon-Barua R, Ramirez-Ramos A, Morgan D, Recavarren S, Spira W, Watanabe J, Kraft W, Bender M, Pearson A (1987) Efficacy of nitrofurans in the treatment of antral gastritis associated with Campylobacter pylori. Campylobacter pylori — A multi-disciplinary workshop, Keystone, Colorado, July 28–31

    Google Scholar 

  22. Glupczinsky Y, Bruck C, Burette A, Labbe M, Delmee M, Avesani V and Bogaerts J (1987) Comparative in-vitro activity of 21 antimicrobial and antiulcer agents against clinical isolates of Campylobacter pyloridis. Abstract No. 58 IVth International Workshop on Campylobacter Infections, Göteborg, Sweden, June 16–18

    Google Scholar 

  23. Glupczynski Y, Labre M, Burette A, Delmee M, Avesani V, Bruck C (1987) Treatment failure of ofloxacin in Campylobacter pylori infection. Lancet i: 1096

    Article  Google Scholar 

  24. Goodwin CS, Armstrong JA (1986) Will antibacterial chemotherapy be efficacious for gastritis and peptic ulcer? J Antimicrob Chemother 17: 1

    Article  PubMed  CAS  Google Scholar 

  25. Goodwin CS, Blake P, Blincow E (1986) The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis. J Antimicrob Chemother 17: 309

    Article  PubMed  CAS  Google Scholar 

  26. Goodwin CS, Marshall BJ, Warren JR, Blackbourn S, Blincow ED (1987) Clearance of Campylobacter pyloridis, and reduced duodenal ulcer relapse with bismuth and tinidazole compared to Cimetidine. Abstract No. 60, IVth International Workshop on Campylobacter Infections, Göteborg, Sweden, June 16–18

    Google Scholar 

  27. Hamilton I, O’Connor HJ, Wood NC, Bradbury I, Axon ATR (1986) Healing and recurrence of duodenal ulcer after treatment with tripotassium dicitrato bismuthate (TDB) tablets or Cimetidine. Gut 27: 106

    Article  PubMed  CAS  Google Scholar 

  28. Harley H, Alp MH (1983) Treatment of chronic duodenal ulceration. Effectiveness of colloidal bismuth subcitrate tablets compared with Cimetidine. Med J Aust 2: 627

    PubMed  CAS  Google Scholar 

  29. Hazell SL, Lee A, Brady L, Hennessey W (1986) Campylobacter pyloridis and gastritis: association with intracellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium. J Infect Dis 153: 658

    Article  PubMed  CAS  Google Scholar 

  30. Hirschl A, Stanek G, Pötzi R, Rotter M, Wende L (1986) Die Empfindlichkeit von Campylobacter pyloridis gegenüber antimikrobiellen Chemotherapeutika und Ulcus-therapeutika. Z. Antimikrobielle Antineoplastische Chemotherapie 4: 45

    CAS  Google Scholar 

  31. Hirschl AM, Stanek G, Rotter M, Hentschel E, Schütze K (1987) Ulcus duodeni und Antibiotika-Therapie. Dtsch Med Wschr 112: 781

    PubMed  CAS  Google Scholar 

  32. Hirschl AM, Stanek G, Rotter M, Pötzi R, Gangl A, Hentschel E, Schütze K, Holzner JH, Nemec H (1987) Campylobacter pyloridis, Gastritis und Ulcus pepticum. Wien Med Wschr 99: 493

    CAS  Google Scholar 

  33. Howden A, Boswell P, Tovey F (1986) In-vitro sensitivity of Campylobacter pyloridis to furazolidone in peptic ulcer. Lancet ii: 1048

    Google Scholar 

  34. Johnston BJ, Reed PI, Ali MH (1987) Prevalance of Campylobacter pylori in duodenal and gastric mucosa — relationship to inflammation. Campylobacter pylori -A multi-disciplinary workshop, Keystone, Colorado, July 28–31

    Google Scholar 

  35. Kalenic S, Falisevac V, Scukanec-Spoljar M, Gmajnicki B, Knezevic S, Vodopija I (1987) Ofloxacin and Metronidazole activity on gastritis and peptic ulcer associated with Campylobacter pylori. Abstract No. 75 IVth International Workshop on Campylobacter Infections. Göteborg, Sweden, June 16–18

    Google Scholar 

  36. Kang JY, Piper DW (1982) Cimetidine and colloidal bismuth in treatment of chronic duodenal ulcer. Digestion 23: 73

    Article  PubMed  CAS  Google Scholar 

  37. Kasper G, Dickgiesser N (1984) Antibiotic sensitivity of “Campylobacter pylori” Eur J Clin Microbiol 3: 444

    Article  PubMed  CAS  Google Scholar 

  38. Lam SK, Lee NW, Koo J, Hui WM, Fok KH, Ng M (1984) A randomised cross-over trial of tripotassium dicitrato bismuthate vs high dose Cimetidine for duodenal ulcers resistant to standard dose of Cimetidine. Gut 25: 703

    Article  PubMed  CAS  Google Scholar 

  39. Lambert JR, Borromeo M, Korman MG, Hansky J (1987) Role of Campylobacter pyloridis in non-ulcer dyspepsia — A randomized controlled trial. Gastroenterol 92: 1488

    Google Scholar 

  40. Lambert JR, Hansky J, Davidson A, Pinkard K, Stockman K (1985) Campylobacter like organisms (CLO) — in vivo and in vitro susceptibility to antimicrobial and antiulcer therapy. Gastroenterol 88: 1462

    Google Scholar 

  41. Lambert T, Mégraud F, Gerbaud G, Courvalin P (1986) Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents. Antimicrob Ag Chemother 30: 510

    CAS  Google Scholar 

  42. Lamouliatte H, Megraud F, de Mascarel A, Quinton A (1987) Placebo-controlled trial of josamycin in Campylobacter pyloridis associated gastritis. Abstract No 190, IVth International Workshop on Campylobacter Infections, Göteborg, Sweden, June 16–18

    Google Scholar 

  43. Langenberg ML, Rauws EAJ, Houthoff HJ, Oudbier J, Tytgat GNJ, Zanen HC (1987) Follow-up of C. pyloridis-associated gastritis after treatment with amoxycillin and/or colloidal bismuthsubcitrate. Abstract No. 94, IVth International Workshop on Campylobacter Infections, Göteborg, Sweden, June 16–18

    Google Scholar 

  44. Lastovica AJ, Hill I, Emms M, Sinclair-Smith CC (1987) Campylobacter pyloridis associated with protein-losing enteropathy in paediatric patients. Abstract No. 95, IVth International Workshop on Campylobacter Infections, Göteborg, Sweden, June 16–18

    Google Scholar 

  45. Lee, FI, Samloff IM, Hardman M (1985) Comparison of tri-potassium dicitrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers. Lancet i: 1299

    Article  Google Scholar 

  46. Leunk RD, Johnson PT, David BC, Kraft WG and Morgan DR (1987) Identification of cytotoxic activity produced by Campylobacter pyloridis. Abstract No. 97, IVth International Workshop on Campylobacter Infections, Göteborg, Sweden, June 16–18

    Google Scholar 

  47. Malfertheiner P, Bode G, Vanek E, Stanescu A, Lutz E, Blessing J und Ditschuneit H (1987) Campylobacter pylori — Is there a connection with peptic ulcer? Dtsch Med Wschr 112: 493

    Article  PubMed  CAS  Google Scholar 

  48. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ (1985) Attempt to fulfil Koch’s postulates for pyloric Campylobacter. Med J Aust 142: 436

    PubMed  CAS  Google Scholar 

  49. Marshall BJ, Barrett LJ, Guerrant RL (1987) Protection of Campylobacter pyloridis but not Campylobacter jejuni against acid susceptibility by urea. Abstract No. 221, IVth International Workshop on Campylobacter Infections, Göteborg, Sweden, June 16–18

    Google Scholar 

  50. Marshall BJ, Goodwin CS, Warren JR, Murray R, Blincow E, Blackbourn S, Phillips M, Waters T, Sanderson C (1987) Long term healing of gastritis and low duodenal ulcer relapse after eradication of Campylobacter pyloridis: A prospective double-blind study. Gastroenterol 92: 1518

    Google Scholar 

  51. Marshall BJ, McGechie DB, Francis GJ, Utley PJ (1984) Pyloric Campylobacter serology. Lancet ii: 281

    Article  Google Scholar 

  52. Martin DF, Hollanders D, May SJ, Ravenscroft MM, Tweedle DE, Miller JP (1981) Difference in relapse rates of duodenal ulcer after healing with Cimetidine or tripotas-sium dicitrato bismuthate. Lancet I: 7

    Article  Google Scholar 

  53. Martin-Bouyer G et al. (1987) Epidemiological study of encephalopathies following bismuth administration per os. Clin Toxicol 18: 1277

    Article  Google Scholar 

  54. McNulty CAM, Dent JC, Ford GA, Wilkinson SP (1987) Antimicrobial concentrations in the gastric mucosa. IVth International Workshop on Campylobacter Infections. Göteborg, Sweden, June 16–18, abstract 113

    Google Scholar 

  55. McNulty CAM, Dent J, Wise R (1985) Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents. Antimicrobial Agents and Chemotherapy 28: 837

    PubMed  CAS  Google Scholar 

  56. McNulty CAM, Gearty JC, Crump B, Davis M, Donovan IA, Melikian V, Lister DM, Wise R (1986) Cympylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erthromycin ethylsuccinate. Br Med J 293: 645

    Article  CAS  Google Scholar 

  57. Menge H, Hofmann J, Gregor M (1987) Dosis-Wirkungs-Studien mit Wismutsalzen zur Elimination von Campylobacter pylori. Z Gastroenterol 25 [Suppl 4]: 44

    PubMed  Google Scholar 

  58. Morgan DR, Fitzpatrick PM, David KL, Kraft WG (1987) Susceptibility patterns of Campylobacter pyloridis. FEMS Microbiol Letters 42: 245

    Article  CAS  Google Scholar 

  59. Morris A, Nicholson G (1987) Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 82: 192

    PubMed  CAS  Google Scholar 

  60. Penfold SS, Lastovica AJ, Elisha BG (1987) Demonstration of plasmids in C. pyloridis. Abstract No. 126, IVth International Workshop on Campylobacter Infections, Göteborg, Sweden, June 16–18

    Google Scholar 

  61. Quintero M et al. (1974) Estudio clinico-experimental del metronidazol en el trata-miento de la ulcera peptica. Rev Cuba Med 13: 37

    Google Scholar 

  62. Quintero M, Sotto A (1986) Metronidazole versus Cimetidine in treatment of gastro-duodenal ulcer. Lancet i: 907

    Article  Google Scholar 

  63. Rathbone BJ, Wyatt JI, Tompkins DS, Heatley RV (1987) Gastric mucosal production of Campylobacter pyloridis antibodies in in vitro. Abstract No. 135, IVth International Workshop on Campylobacter Infections, Göteborg, Sweden, June 16–18

    Google Scholar 

  64. Sancho-Minano J et al (1969) Evolución clinica y radiológica de la úlcera gastroduode-nal tratada con metronidazol. Progres Ter Clin 22: 225

    Google Scholar 

  65. Schaub N, Stalder H, Vischer W, Stalder GA, Affolter H, Wegmann W (1987) Versagen von Doxycyclin bei Campylobacter-pylori-positiver Gastritis. Dtsch Med Wschr 112: 117

    PubMed  CAS  Google Scholar 

  66. Schrager J, Spink R, Mitra S (1967) The antrum in patients with duodenal and gastric ulcers. Gut 8: 497

    Article  PubMed  CAS  Google Scholar 

  67. Shirokova Kl et al (1981) Metronidazole in the treatment of peptic ulcer. Klin Med (Moscow) 59: 48

    CAS  Google Scholar 

  68. Shreeve DR, Klass HJ, Jones PE (1983) Comparison of Cimetidine and tripotassium dicitrato bismuthate in healing and relapse of duodenal ulcers. Digestion 28: 96

    Article  PubMed  CAS  Google Scholar 

  69. Skoglund ML, Waiters K, Taulbee J (1987) Bismuth concentration at site of Campylobacter pyloridis colonization. Campylobacter pylori — A multidisciplinary workshop, Keystone, Colorado, July 28–31

    Google Scholar 

  70. Vantrappen G, Schuurmans P, Rutgeerts P, Janssens J (1982) A comparative study of colloidal bismuth subcitrate and Cimetidine on the healing and recurrence of duodenal ulcer. Scand J Gastroent 17 [Suppl 80]: 23

    Google Scholar 

  71. Ward M, Halliday C, Cowen AE (1986) A comparison of colloidal bismuth subcitrate tablets and ranitidine in the treatment of chronic duodenal ulcers. Digestion 34: 173

    Article  PubMed  CAS  Google Scholar 

  72. Warren JR, Marshall BJ (1983) Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet i: 1273

    Google Scholar 

  73. Weiss G, Kallmeyer JC (1968) Pilot trial of a colloidal bismuth preparation in the treatment of peptic ulcer. S Afr Med J 42: 317

    PubMed  CAS  Google Scholar 

  74. Weiss G, Serfontein WJ (1971) The efficacy of a bismuth-protein-complex compound in the treatment of gastric and duodenal ulcers. SA Med J 45: 467

    CAS  Google Scholar 

  75. Wyatt JI, Rathbone BJ, Dixon MF, Heatley RV (1987) Campylobacter pyloridis and acid induced gastric metaplasia in the pathogeneis of duodenitis. J Clin Pathol 40: 841–848

    Article  PubMed  CAS  Google Scholar 

  76. Zhao HY, Li G, Guo J, Yan Z, Sun S, Li L, Duan Y, Yue F (1985) Furazolidone in peptic ulcer. Lancet II: 276

    Google Scholar 

  77. Zheng ZT, et al. (1982) The long-term trial and experimental studies of furazolidone in peptic ulcers. Chin. J. Dig. 2: 131

    Google Scholar 

  78. Zheng ZT, Wang ZY, Chu YX, Li YN, Li OF, Lin SR, Xu ZM (1985) Double-blind short-term trial of furazolidone in peptic ulcer. Lancet I: 1048

    Google Scholar 

Download references

Authors
  1. E. Bayerdörffer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. I. Medizinische Abteilung, Städtisches Krankenhaus München-Neuperlach, Oskar-Maria-Graf-Ring 51, 8000, München 83, Deutschland

    R. Ottenjann  & W. Schmitt  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer Verlag Berlin Heidelberg

About this paper

Cite this paper

Bayerdörffer, E. (1988). Bedeutung der Elimination von Campylobacter pylori in der Ulkustherapie. In: Ottenjann, R., Schmitt, W. (eds) Aktuelle Gastroenterologie — Campylobacter pylori. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-85515-3_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-85515-3_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-19310-4

  • Online ISBN: 978-3-642-85515-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation